Shares of ACADIA Pharmaceuticals (ACAD -1.98%) shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial results for the company's drug Pimavanserin, which treats psychosis in patients with Parkinson's disease. David tells investors how good the results were, and what advantages this drug candidate could have over its competition if it reaches FDA approval.
S&P 500
5,997.94
+1.0%
+$58.64
DJI
42,811.54
+1.2%
+$491.80
NASDAQ
19,517.26
+1.1%
+$218.81
Bitcoin
104,004.00
-1.7%
-1,787.77
AAPL
$204.87
+2.1%
+$4.24
AMZN
$211.45
+1.7%
+$3.54
GOOG
$172.86
+1.8%
+$3.05
META
$697.16
+1.8%
+$12.54
MSFT
$470.22
+0.5%
+$2.54
NVDA
$142.04
+1.5%
+$2.05
TSLA
$299.00
+5.0%
+$14.30
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.